Navigation Links
Drugs from the sea: New discoveries in marine biomedicine
Date:5/13/2011

Substances produced by living organisms found in natureso-called "natural products"have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

To raise awareness about the vast potential of marine- and natural product-based biotechnology in the discovery and development of new drugs, the New York Academy of Sciences and the marine-based drug development company Zeltia S.A. are hosting a symposium, "New Frontiers in Marine Drug Discovery" at the New York Academy of Sciences Conference Center on May 20, 2011. This symposium will address the newly discovered and tremendous potential that the biodiversity of the marine ecosystem offers as a source for new therapeutically useful compounds, from the early stage drug discovery perspective of academia and the clinical therapy development perspective of industry.

The event will showcase recent technological improvements in natural product chemistry; review the landscape of marine-derived compoundsboth approved drugs and those in the development and trial stages; and explore examples of pioneering efforts, failures and successes in the translation of small molecules of natural marine origin into first-in-class and life-changing therapies for metastatic ovarian and metastatic breast cancer, among other diseases.

WHAT: A Scientific Symposium: New Frontiers in Marine Drug Discovery

WHO:

  • William Fenical, PhD, Director, Scripps Institution of Oceanography
  • Shirley Pomponi, PhD, President and CEO, Harbor Branch Oceanographic Institution
  • Juli M. Trtanj, Director, Oceans and Human Health Initiative, NOAA National Ocean Service
  • Roberto Weinmann, PhD, COO PharmaMar USA, a company of the Zeltia Group

WHEN: Friday May 20, 2011 | 8:00 AM - 7:00 PM

WHERE:
The New York Academy of Sciences
7 World Trade Center, 250 Greenwich St., 40th floor, New York, NY


'/>"/>

Contact: Marta Murcia
mmurcia@nyas.org
212-298-8641
New York Academy of Sciences
Source:Eurekalert

Related biology news :

1. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
2. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
3. Discovering drugs, biofuels in tropical seas
4. Academy participates in project to discover drugs, biofuels in tropical seas
5. European researchers harness unique properties of boron to develop new drugs and diagnostics
6. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
7. Moderate use averts failure of type 2 diabetes drugs in animal model
8. Montana State University researchers find gene that regulates molds resistance to drugs
9. MSU researcher studies ties between cholesterol drugs, muscle problems
10. New technique eliminates toxic drugs in islet transplant in diabetic mice
11. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology: